Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia
Sponsor
Eli Lilly and Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00034801
Collaborator
(none)
378
30
17.9
12.6
0.7
Study Details
Study Description
Brief Summary
This is a research study comparing the safety and efficacy of two active study medications
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Study Design
Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Official Title:
A Controlled Trial of Olanzapine Versus Active Comparator in the Treatment of Schizophrenic and Schizoaffective Subjects With Comorbid Depression
Study Start Date
:
Sep 1, 2001
Study Completion Date
:
Mar 1, 2003
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
Male or female subjects 18-60 years of age
-
Female subjects of childbearing potential must be using a medically accepted means of contraception
-
Each subject must have a level of understanding sufficient to perform all tests and examinations required by the protocol
-
Subjects must be considered reliable
Exclusion Criteria:
-
Treatment with a drug within the last 30 days that has not received regulatory approval at the time of study entry
-
Female subjects who are either pregnant or nursing
-
Uncorrected hypothyroidism or hyperthyroidism
-
Narrow-angle glaucoma
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Tuscaloosa | Alabama | United States | ||
2 | Little Rock | Arkansas | United States | ||
3 | Anaheim | California | United States | ||
4 | Chula Vista | California | United States | ||
5 | Lafayette | California | United States | ||
6 | Long Beach | California | United States | ||
7 | Orange | California | United States | ||
8 | Poway | California | United States | ||
9 | Rosemeade | California | United States | ||
10 | San Diego | California | United States | ||
11 | Denver | Colorado | United States | ||
12 | New Britain | Connecticut | United States | ||
13 | Winter Park | Florida | United States | ||
14 | Augusta | Georgia | United States | ||
15 | Prairie Village | Kansas | United States | ||
16 | Gaithersburg | Maryland | United States | ||
17 | Mt Pleasant | Michigan | United States | ||
18 | St Louis | Missouri | United States | ||
19 | Lincoln | Nebraska | United States | ||
20 | Clementon | New Jersey | United States | ||
21 | Buffalo | New York | United States | ||
22 | New York | New York | United States | ||
23 | Staten Island | New York | United States | ||
24 | Charlotte | North Carolina | United States | ||
25 | Philadelphia | Pennsylvania | United States | ||
26 | Sioux Falls | South Dakota | United States | ||
27 | Austin | Texas | United States | ||
28 | El Paso | Texas | United States | ||
29 | Houston | Texas | United States | ||
30 | Salt Lake City | Utah | United States |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
,
,
ClinicalTrials.gov Identifier:
NCT00034801
Other Study ID Numbers:
- 5529
- F1D-US-HGJU
First Posted:
May 3, 2002
Last Update Posted:
Jul 19, 2006
Last Verified:
Jul 1, 2006
Keywords provided by ,
,
Additional relevant MeSH terms: